In adults with obesity, a review of phase 2 and 3 trials reports that tirzepatide achieved weight reductions exceeding 20%.
In plain wordsIn adults with obesity, a review reports that tirzepatide led to weight loss of more than 20%.
- Peptide
- Tirzepatide
- Outcome
- DecreaseWeight reduction
- Study
n: not reported in source
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- Dose not stated
Measurements
- weight reduction
- > 20%
- tirzepatide
Source sentences
Tirzepatide, CagriSema, and amycretin achieved weight reductions exceeding 20%
2 context sentences(design, population, supporting numbers)
A systematic literature search of the Medline database using MeSH terms and keywords related to new-generation obesity pharmacotherapy was conducted to identify articles published between 2021 and 2026.
Phase 2 and 3 clinical trials evaluating emerging obesity pharmacotherapies in adults and reporting outcomes, including weight loss and obesity-related complications, were included.